Covid19 Clinical Trial
Official title:
TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Verified date | March 2022 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Interferon (IFN) lambda is one of the fundamental responses of the innate immune system. Peginterferon lambda is a long-acting form that has been studied extensively in human trials in viral hepatitis, confirming it safety and tolerability. It is particularly attractive for consideration in the use of acute respiratory illness due to the high expression of the lambda receptor in lung epithelia. We propose to evaluate peginterferon-lambda in ambulatory patients with mild to moderate COVID-19.
Status | Active, not recruiting |
Enrollment | 763 |
Est. completion date | June 30, 2022 |
Est. primary completion date | March 21, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Adult 18 years of age or older. 2. Symptomatic and within 7 days of symptom onset. 3. High risk for severe disease (as defined by one or more of the following): 1. Age >50 2. Diabetes mellitus requiring therapy 3. Hypertension on medication 4. BMI >30 kg/m2 5. Cardiovascular disease 6. Asthma requiring chronic controller medication 7. Symptomatic respiratory disease 8. Immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) 9. Documented fever (>38C) 10. One or more of the following symptoms: cough, shortness of breath (SOB), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) 4. Discharged to home isolation. 5. Willing and able to provide informed consent (including by substitute decision maker). 6. Willing and able to follow-up by phone or videoconference. 7. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. Exclusion Criteria: 1. Pregnancy (or positive urine pregnancy test) or lactating. 2. More than 14 days following completion of SARS-CoV-2 vaccition series 3. The following pre-existing medical conditions: 1. Known cirrhosis with any history of decompensation (ascites, variceal bleeding or hepatic encephalopathy) 2. Known chronic kidney disease with estimated creatinine clearance < 30 mL/minute or need for dialysis 3. Uncontrolled severe psychiatric disorder - schizophrenia, bipolar disorder, depression with prior suicidality 4. Uncontrolled seizures or seizure in the prior 1 month 5. Any other underlying medical (cardiac, liver, renal, neurological, respiratory) or psychiatric condition that in the view of the investigator would preclude use of peginterferon lambda 4. Known alcohol or drug dependence that in the opinion of the investigator would impair study participation. 5. Known prior intolerance to interferon treatment. 6. Enrolment in another clinical trial testing an antiviral agent or receipt of an antiviral agent for COVID-19 in the past 7 days. 7. Use of investigational, off-label therapy for COVID-19, or unproven therapy for COVID-19. |
Country | Name | City | State |
---|---|---|---|
Canada | Toronto General Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | COVID-19 related urgent care visit, emergency room assessment, hospitalization or death by Day 28 (Primary efficacy endpoint) | Proportion with COVID-19-related emergency room assessment, hospitalization, or death by Day 28 | At day 28 | |
Primary | SARS-CoV-2 RNA negativity (Primary virological endpoint) | The time to SARS-CoV-2 RNA negativity. | Day 0 to Day 28 | |
Primary | Treatment-emergent and treatment-related serious adverse events (Primary safety endpoint) | The rate of treatment-emergent and treatment-related serious adverse events (SAEs) by Day 28. | Day 0 to Day 28 | |
Secondary | Respiratory symptom resolution (Clinical Outcome #1) | Time to resolution of respiratory symptoms. | Day 0 to Day 28 | |
Secondary | Hospitalization (Clinical outcome #2) | Hospitalization for any cause | Day 0 to Day 28 | |
Secondary | Death (Clinical outcome #3) | Death due to respiratory or cardiovascular causes | Day 0 to Day 28 | |
Secondary | All symptom resolution (Clinical outcome #4) | Time to resolution of all symptoms (return to usual state of heath). | Day 0 to Day 28 | |
Secondary | Oxygen saturation on room air (Clinical outcome #5) | Proportion of days with oxygen saturation below 93% on room air by Day 14 | Day 0 to Day 14 | |
Secondary | Seeking care from healthcare professional for COVID-19 (Clinical outcome #6) | Proportion seeking care from primary care provider/walk-in clinic or study healthcare provider for COVID-19. | Day 0 - Day 14 | |
Secondary | Hospital Admission (Clinical outcome #7) | Duration of hospital admission up to Day 28 | Day 0 to Day 28 | |
Secondary | Time to viral negativity (Virologic/immunological outcome #1) | Time to SARS-CoV-2 RNA negativity. | Day 0 to Day 14 | |
Secondary | Mean log of SARS-CoV-2 RNA (Virologic/immunological outcome #2) | Difference in mean SARS-CoV-2 RNA in log copies/mL | Day 3, 5, 7, 10 and 14 | |
Secondary | Mean log decline in SARS-CoV-2 RNA (Virologic/immunological outcome #3) | Difference in mean log decline in SARS-CoV-2 RNA. | Day 3, 5, 7, 10 and 14 | |
Secondary | Negative for SARS-CoV-2 RNA (Virologic/immunological outcome #4) | Proportion negative for SARS-CoV-2 RNA. | Day 3 | |
Secondary | Negative for SARS-CoV-2 RNA (Virologic/immunological outcome #5) | Proportion negative for SARS-CoV-2 RNA. | Day 7 | |
Secondary | Negative for SARS-CoV-2 RNA (Virologic/immunological outcome #6) | Proportion negative for SARS-CoV-2 RNA. | Day 14 | |
Secondary | Proportion with antibodies (Virologic/immunological outcome #7) | Proportion with SARS-CoV-2 antibodies in blood. | Day 0, 7, 14 and 90 | |
Secondary | Correlation with interferon lambda 4 genotype (Virologic/immunological outcome #8) | Correlation of response with interferon lambda 4 (IFNL4) genotype. | Day 0 to Day 28 | |
Secondary | Laboratory markers (Virologic/immunological outcome #9) | Change in hemoglobin over time | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #10) | Change in white blood cell count over time | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #11) | Change in lymphocyte count over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #12) | Change in ALT over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #13) | Change in AST over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #14) | Change in ALP over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Laboratory markers (Virologic/immunological outcome #15) | Change in total bilirubin over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Inflammatory markers (Virologic/immunological outcome #16) | Change in lactate dehydrogenase over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Inflammatory markers (Virologic/immunological outcome #17) | Change in c-reactive protein over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Inflammatory markers (Virologic/immunological outcome #18) | Change in D-dimers over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | Inflammatory markers (Virologic/immunological outcome #19) | Change in creatine kinase over time. | Day 0 to Day 7 and Day 7 to Day 14. | |
Secondary | COVID-19 in household contacts (Transmission outcome #1) | Confirmed diagnosis of COVID-19 in household contacts. | Day 0 to Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |